Singular Genomics Systems Inc
NASDAQ:OMIC
Singular Genomics Systems Inc
Research & Development
Singular Genomics Systems Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Singular Genomics Systems Inc
NASDAQ:OMIC
|
Research & Development
-$47.8m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Research & Development
-$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Danaher Corp
NYSE:DHR
|
Research & Development
-$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Research & Development
-$199.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Research & Development
-$450m
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-3%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Singular Genomics Systems Inc
Glance View
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. The company is headquartered in La Jolla, California and currently employs 221 full-time employees. The company went IPO on 2021-05-27. The firm has developed an NGS technology or sequencing engine. The company is developing two integrated solutions that are built to target specific applications. The firm's first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which is collectively referred as G4 Integrated Solution. The G4 Instrument is a sequencer designed to produce accurate genetic sequencing results. Its second integrated solution in development comprises an instrument and an associated menu of consumable kits, which is collectively referred as PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a multiomics solution.
See Also
What is Singular Genomics Systems Inc's Research & Development?
Research & Development
-47.8m
USD
Based on the financial report for Dec 31, 2023, Singular Genomics Systems Inc's Research & Development amounts to -47.8m USD.
What is Singular Genomics Systems Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-31%
Over the last year, the Research & Development growth was -3%. The average annual Research & Development growth rates for Singular Genomics Systems Inc have been -31% over the past three years .
